ASX:KZAKazia Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kazia Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day RangeA$0.40MA: A$0.40▼A$0.4052-Week Range N/AVolume47,736 shsAverage VolumeN/AMarket Capitalization$28.87 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Kazia Therapeutics. Previous Next 2.4 Community Rank Outperform VotesKazia Therapeutics has received 14 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKazia Therapeutics has received 15 “underperform” votes. (Add your “underperform” vote.)Community SentimentKazia Therapeutics has received 51.72% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kazia Therapeutics and other stocks. Vote “Outperform” if you believe KZA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KZA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKazia Therapeutics does not currently pay a dividend.Dividend GrowthKazia Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kazia Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$51,375.00 in company stock and sold A$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Kazia Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kazia Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.08 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:KZA Previous Symbol CUSIPN/A CIKN/A Webwww.kaziatherapeutics.com Phone61 2 9472 4101Debt Debt-to-Equity RatioN/A Current Ratio2.44 Quick Ratio2.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.40 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.49 Book ValueA$0.17 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares72,166,704Market Cap$28.87 million Next Earnings DateN/A OptionableNot Optionable Receive KZA News and Ratings via Email Sign-up to receive the latest news and ratings for KZA and its competitors with MarketBeat's FREE daily newsletter. Kazia Therapeutics (ASX:KZA) Frequently Asked Questions Has Kazia Therapeutics been receiving favorable news coverage? News stories about KZA stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kazia Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Kazia Therapeutics. Who are some of Kazia Therapeutics' key competitors? Some companies that are related to Kazia Therapeutics include Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), Cocrystal Pharma (COCP), Cocrystal Pharma (COCP), CorMedix (CRMD), CorMedix (CRMD), Antibe Therapeutics (ATE), Oncolytics Biotech (ONC), Redx Pharma (REDX), AquaBounty Technologies (AQB), OKYO Pharma (OKYO), Arix Bioscience (ARIX), 22nd Century Group (XXII), Rezolute (RZLT) and Predictive Technology Group (PRED). View all competitors. Who are Kazia Therapeutics' key executives? Kazia Therapeutics' management team includes the following people: Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)Ms. Gabrielle Heaton, Director of Fin. & Admin.Ms. Catherine Jane Hill, Company Sec. (Age 60)Kym Robins, Director of Marketing & CommunicationsDr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program What is Kazia Therapeutics' stock symbol? Kazia Therapeutics trades on the ASX under the ticker symbol "KZA." How big of a company is Kazia Therapeutics? Kazia Therapeutics has a market capitalization of $0.00 and generates $1.40 million in revenue each year. What is Kazia Therapeutics' official website? The official website for Kazia Therapeutics is www.kaziatherapeutics.com. How can I contact Kazia Therapeutics? The company can be reached via phone at 61 2 9472 4101. This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
